SLC46A3 explained

Solute carrier family 46 member 3 (SLC46A3) is a protein that in humans is encoded by the SLC46A3 gene.[1] Also referred to as FKSG16, the protein belongs to the major facilitator superfamily (MFS) and SLC46A family.[2] Most commonly found in the plasma membrane and endoplasmic reticulum (ER), SLC46A3 is a multi-pass membrane protein with 11 α-helical transmembrane domains.[3] It is mainly involved in the transport of small molecules across the membrane through the substrate translocation pores featured in the MFS domain.[4] [5] The protein is associated with breast and prostate cancer, hepatocellular carcinoma (HCC), papilloma, glioma, obesity, and SARS-CoV.[6] [7] [8] [9] [10] [11] Based on the differential expression of SLC46A3 in antibody-drug conjugate (ADC)-resistant cells and certain cancer cells, current research is focused on the potential of SLC46A3 as a prognostic biomarker and therapeutic target for cancer.[12] While protein abundance is relatively low in humans, high expression has been detected particularly in the liver, small intestine, and kidney.[13] [14]

Gene

The SLC46A3 gene, also known by its aliases solute carrier family 46 member 3 and FKSG16, is located at 13q12.3 on the reverse strand in humans. The gene spans 18,950 bases from 28,700,064 to 28,719,013 (GRCh38/hg38), flanked by POMP upstream and CYP51A1P2 downstream.[15] SLC46A3 contains 6 exons and 5 introns. There are two paralogs for this gene, SLC46A1 and SLC46A2, and orthologs as distant as fungi.[16] So far, more than 4580 single nucleotide polymorphisms (SNPs) for this gene have been identified.[17] SLC46A3 is expressed at relatively low levels, about 0.5x the average gene.[18] Gene expression is peculiarly high in the liver, small intestine, and kidney.

Transcript

Transcript Variants

SLC46A3 has multiple transcript variants produced by different promoter regions and alternative splicing.[19] A total of 4 transcript variants are found in the RefSeq database.[20] Variant 1 is most abundant.[21]

Transcript Variants of SLC46A3!Transcript Variant!Accession Number!Length (bp)!Description
1NM_181785.43302MANE select. Variant 1 encodes isoform a.
2[22] NM_001135919.22758Variant 2 encodes isoform b. It lacks a segment in the 3' coding region and the resulting frameshift causes isoform b to have a longer C-terminus than isoform a.
3[23] NM_001347960.13099Variant 3 also encodes isoform a. Variants 1 and 3 differ in their 5' untranslated regions (UTRs).
X1[24] XM_005266361.21845Variant X1 encodes isoform X1.
*Lengths shown do not include introns.

Protein

Isoforms

3 isoforms have been reported for SLC46A3. Isoform a is MANE select and most abundant.[25] All isoforms contain the MFS and MFS_1 domains as well as the 11 transmembrane regions.[26] [27] [28]

Isoforms of the SLC46A3 Protein!Isoform!Accession Number!Length (aa)!Transcript
aNP_861450.1NP_001334889.14611,3
bNP_001129391.14632
X1XP_005266418.1463X1
*Lengths shown are for the precursor proteins.

Properties

SLC46A3 is an integral membrane protein 461 amino acids (aa) of length with a molecular weight (MW) of 51.5 kDa.[29] The basal isoelectric point (pI) for this protein is 5.56. The protein contains 11 transmembrane domains in addition to domains MFS and MFS_1. MFS and MFS_1 domains largely overlap and contain 42 putative substrate translocation pores that are predicted to bind substrates for transmembrane transport. The substrate translocation pores have access to both sides of the membrane in an alternating fashion through a conformational change. SLC46A3 lacks charged and polar amino acids while containing an excess of nonpolar amino acids, particularly phenylalanine (Phe). The resulting hydrophobicity is mostly concentrated in the transmembrane regions for interactions with the fatty acid chains in the lipid bilayer.[30] The transmembrane domains also have a shortage of proline (Pro), a helix breaker.The protein sequence contains mixed, positive, and negative charge clusters, one of each, which are high in glutamine (Glu). The clusters are located outside the transmembrane regions, and thus are solvent-exposed. Two 0 runs that run through several transmembrane domains in addition to a +/* run in between two transmembrane domains are also present. The protein contains a C-(X)2-C motif (CLLC), which is mostly present in metal-binding proteins and oxidoreductases.[31] A sorting-signal sequence motif, YXXphi, is also found at Tyr246 - Phe249 (YMLF) and Tyr446 - Leu449 (YELL).[32] [33] This Y-based sorting signal directs the trafficking within the endosomal and the secretory pathways of integral membrane proteins by interacting with the mu subunits of the adaptor protein (AP) complex.[34] The signal-transducing adaptor protein 1 (STAP1) Src homology 2 (SH2) domain binding motif at Tyr446 - Ile450 (YELLI) is a phosphotyrosine (pTyr) pocket that serves as a docking site for the SH2 domain, which is central to tyrosine kinase signaling.[35] Multiple periodicities typical of an α-helix (periods of 3.6 residues in the hydrophobicity) encompass transmembrane domains.[36] 3 tandem repeats with core block lengths of 3 aa (GNYT, VSTF, STFI) are observed throughout the sequence.

Secondary Structure

Based on results by Ali2D, the secondary structure of SLC46A3 is rich in α-helices with random coils in between.[37] More precisely, the protein is predicted to be composed of 62.9% α-helix, 33.8% random coil, and 3.3% extended strand. The regions of α-helices span the majority of the transmembrane domains. The signal peptide is also predicted to form an α-helix, most likely in the h-region.[38] The amphipathic α-helices possess a particular orientation with charged/polar and nonpolar residues on opposite sides of the helix mainly due to the hydrophobic effect.[39] Membrane topology of SLC46A3 shows the 11 α-helical transmembrane domains embedded in the membrane with the N-terminus oriented toward the extracellular region (or lumen of the ER) and the C-terminus extended to the cytoplasmic region.[40] [41]

Tertiary Structure

Model for the tertiary structure of SLC46A3 was constructed by I-TASSER based on a homologous crystal structure of the human organic anion transporter MFSD10 (Tetran) with a TM-score of 0.853.[42] [43] [44] The structure contains a cluster of 17 α-helices that spans the membrane and random coils that connect those α-helices. Multiple ligand binding sites are also predicted to reside in the structure, including those for (2S)-2,3-dihydroxypropyl(7Z)-pentadec-7-enoate (78M), cholesterol hemisuccinate (Y01), and octyl glucose neopentyl glycol (37X).[45] [46]

Ligand Binding Sites of SLC46A3!Ligand!C-score!Cluster Size!Ligand Binding Site Residues
78M0.053112, 116, 197, 198, 201, 204, 208
Y010.05389, 241, 265, 269, 273, 391, 394, 399
37X0.03286, 89, 90, 94, 109, 136

Regulation of Gene Expression

Gene Level Regulation

Promoter

SLC46A3 carries 4 promoter regions that lead to different transcript variants as identified by ElDorado at Genomatix. Promoter A supports transcript variant 1 (GXT_2836199).

SLC46A3 Promoters!Promoter!Name!Start!End!Length (bp)!Transcript
AGXP_19067828718802287200921291GXT_2775378, GXT_29165870, GXT_23385588, GXT_2836199, GXT_26222267, GXT_22739111, GXT_23500299
BGXP_19067628714934287159731040GXT_2785139
CGXP_19067928713272287143111040GXT_2781051
DGXP_1967728704518287055571040GXT_2781071
*The coordinates are for GRCh38.

Transcription Factors

Transcription factors (TFs) bind to the promoter region of SLC46A3 and modulate the transcription of the gene.[47] The table below shows a curated list of predicted TFs. MYC proto-oncogene (c-Myc), the strongest hit at Genomatix with a matrix similarity of 0.994, dimerizes with myc-associated factor X (MAX) to affect gene expression in a way that increases cell proliferation and cell metabolism.[48] [49] Its expression is highly amplified in the majority of human cancers, including Burkitt's lymphoma. The heterodimer can repress gene expression by binding to myc-interacting zinc finger protein 1 (MIZ1), which also binds to the promoter of SLC46A3. CCAAT-displacement protein (CDP) and nuclear transcription factor Y (NF-Y) have multiple binding sites within the promoter sequence (3 sites for CDP and 2 sites for NF-Y). CDP, also known as Cux1, is a transcriptional repressor.[50] NF-Y is a heterotrimeric complex of three different subunits (NF-YA, NF-YB, NF-YC) that regulates gene expression, both positively and negatively, by binding to the CCAAT box.[51]

SLC46A3 Transcription Factors!Transcription Factor!Description!Matrix Similarity
HIFhypoxia inducible factor0.989
c-Mycmyelocytomatosis oncogene (c-Myc proto-oncogene)0.994
GATA1GATA-binding factor 10.983
PXR/RXRpregnane X receptor / retinoid X receptor heterodimer0.833
RREB1Ras-responsive element binding protein 10.815
TFCP2L1transcription factor CP2-like 1 (LBP-9)0.897
ZNF34zinc finger protein 34 (KOX32)0.852
MIZ1myc-interacting zinc finger protein 1 (ZBTB17)0.962
RFX5regulatory factor X50.758
CEBPBCCAAT/enhancer-binding protein beta0.959
KLF2Kruppel-like factor 2 (LKLF)0.986
CSRNP1cysteine/serine-rich nuclear protein 1 (AXUD1)1.000
CDPCCAAT-displacement protein (CDP/Cux)0.9830.949

0.955

NF-Ynuclear transcription factor Y0.9440.934
ZNF692zinc finger protein 6920.855
KAISOtranscription factor Kaiso (ZBTB33)0.991
SP4transcription factor Sp40.908
ZBTB24zinc finger and BTB domain containing 240.864
E2F4E2F transcription factor 40.982

Expression Pattern

RNAseq data show SLC46A3 most highly expressed in the liver, small intestine, and kidney and relatively low expression in the brain, skeletal muscle, salivary gland, placenta, and stomach.[52] In fetuses of 10 – 20 weeks, the adrenal gland and intestine report high expression while the heart, kidney, lung, and stomach demonstrate the opposite.[53] Microarray data from NCBI GEO present high expression in pancreatic islets, pituitary gland, lymph nodes, peripheral blood, and liver with percentile ranks of 75 or above.[54] Conversely, tissues among the most lowly expressed levels of SLC46A3 include bronchial epithelial cells, caudate nucleus, superior cervical ganglion, smooth muscle, and colorectal adenocarcinoma, all with percentile ranks below 15. Immunohistochemistry supports expression of the gene in the liver and kidney, as well as in skin tissues, while immunoblotting (western blotting) provides evidence for protein abundance in the liver and tonsils, in addition to in papilloma and glioma cells.In situ hybridization data show ubiquitous expression of the gene in mouse embryos at stage E14.5 and the adult mouse brain at postnatal days 56 (P56).[55] [56] In the spinal column of juvenile mouse (P4), SLC46A3 is relatively highly expressed in the articular facet, neural arch, and anterior and posterior tubercles.[57] The dorsal horn shows considerable expression in the cervical spine of adult mouse (P56).[58]

Transcript Level Regulation

RNA-binding Proteins

RNA-binding proteins (RBPs) that bind to the 5' or 3' UTR regulate mRNA expression by getting involved in RNA processing and modification, nuclear export, localization, and translation.[59] A list of some of the most highly predicted RBPs in conserved regions of the 5' and 3' UTRs are shown below.

RNA-binding Proteins in 5' UTR[60] !Protein!Description!Motif!P-value
MBNL1 (muscleblind like splicing regulator 1)modulates alternative splicing of pre-mRNAs; binds specifically to expanded dsCUG RNA with unusual size CUG repeats; contributes to myotonic dystrophyygcuky8.38×10−32.52×10−3
ZC3H10 (zinc finger CCCH-type containing 10)functions as a tumor suppressor by inhibiting the anchorage-independent growth of tumor cells; mitochondrial regulatorssagcgm6.33×10−3
FXR2 (FMR1 autosomal homolog 2)associated with the 60S large ribosomal subunit of polyribosomes; may contribute to fragile X cognitive disability syndromedgacrrr7.01×10−3
SRSF7 (serine/arginine-rich splicing factor 7)critical for mRNA splicing as part of the spliceosome; involved in mRNA nuclear export and translationacgacg6.44×10−3
FMR1 (FMRP translational regulator 1)associated with polyribosomes; involved in mRNA trafficking; negative regulator of translationkgacarg7.53×10−3
HNRNPM (heterogenous nuclear ribonucleoprotein M)influences pre-mRNA processing, mRNA metabolism, and mRNA transportgguugguu5.07×10−3
YBX2 (Y-box binding protein 2)regulates the stability and translation of germ cell mRNAsaacawcd1.68×10−3
RBM24 (RNA binding motif protein 24)a tissue-specific splicing regulator; involved in mRNA stabilitywgwgugd5.83×10−4
PABPC4 (poly(A) binding protein cytoplasmic 4)regulates stability of labile mRNA species in activated T cells; involved in translation in platelets and megakaryocytesaaaaaar5.61×10−3
HuR (human antigen R)stabilizes mRNA by binding AU rich elements (AREs)uukruuu4.61×10−3
RNA-binding Proteins in 3' UTR!Protein!Description!Motif!P-value
ENOX1 (ecto-NOX disulfide-thiol exchanger 1)involved in plasma membrane electron transport (PMET) pathways with alternating hydroquinone (NADH) oxidase and protein disulfide-thiol interchange activitieshrkacag5.17×10−4
CNOT4 (CCR4-NOT transcription complex subunit 4)subunit of CCR4-NOT complex; E3 ubiquitin ligase activity; interacts with CNOT1gacaga5.14×10−4
SRSF3 (serine/arginine-rich splicing factor 3)critical for mRNA splicing as part of the spliceosome; involved in mRNA nuclear export and translationwcwwc4.00×10−4
KHDRBS2 (KH RNA binding domain containing, signal transduction associated 2)influences mRNA splice site selection and exon inclusionrauaaam5.90×10−3
HuR (human antigen R)stabilizes mRNA by binding AREsuukruuu7.12×10−3
RBMS3 (RNA-binding motif, single-stranded-interacting protein 3)(may be) involved in the control of RNA metabolismhauaua1.89×10−3
KHDRBS1 (KH RNA binding domain containing, signal transduction associated 1)involved in alternative splicing, cell cycle regulation, RNA 3'-end formation, tumorigenesis, and regulation of human immunodeficiency virus (HIV) gene expressionauaaaav2.66×10−4
PABPN1 (poly(A) binding protein nuclear 1)binds to nascent poly(A) tails and directs polymerization of poly(A) tails at the 3' ends of eukaryotic transcriptsaraaga9.11×10−3
RBM42 (RNA binding motif protein 42)involved in maintaining cellular ATP levels under stress by protecting target mRNAsaacuamg4.44×10−4

miRNA

Several miRNAs have binding sites in the conserved regions of the 3' UTR of SLC46A3. The following miRNAs can negatively regulate the expression of the mRNA via RNA silencing.[61] Silencing mechanisms include mRNA cleavage and translation repression based on the level of complementarity between the miRNA and mRNA target sequences.

miRNAs[62] [63] !Name!Binding Site Sequence!Target Score
hsa-miR-494-3pATGTTTCA97
hsa-miR-106b-5pGCACTTT – GCACTTT – GCACTTTA94
hsa-miR-7159-5pTTGTTGA – TTGTTGAA94
hsa-miR-5680ATTTCTA – CATTTCT91
hsa-miR-4477bTCCTTAAA – TCCTTAAA91
hsa-miR-660-5pAATGGGT – AATGGGTA89
hsa-miR-4319CTCAGGGA89
hsa-miR-7162-3pACCTCAG89
hsa-miR-137-3pAGCAATAA88
hsa-miR-6071CAGCAGAA88
hsa-miR-597-3pGAGAACCA86
hsa-miR-510-3pTTTCAAA – GTTTCAAA86

Secondary Structure

The secondary structure of RNA holds both structural and functional significance.[64] Among various secondary structure motifs, the stem-loop structure (hairpin loop) is often conserved across species due to its role in RNA folding, protecting structural stability, and providing recognition sites for RBPs.[65] The 5' UTR region of SLC46A3 has 7 stem-loop structures identified and 3' UTR region a total of 10.[66] The majority of the binding sites of RBPs and miRNAs given above are located at a stem-loop structure, which is also true for the poly(A) signal at the 3' end.

Protein Level Regulation

The k-Nearest Neighbor (k-NN) prediction by PSORTII predicts SLC46A3 to be mainly located at the plasma membrane (78.3%) and ER (17.4%), but also possibly at the mitochondrion (4.3%).[67] Immunofluorescent staining of SLC46A3 shows positivity in the plasma membrane, cytoplasm, and actin filaments, although positivity in the latter two is most likely due to the process of the protein being transported by myosin from the ER to the plasma membrane; myosin transports cargo-containing membrane vesicles along actin filaments.[68]

Post-Translational Modification

The SLC46A3 protein contains a signal peptide that facilitates co-translational translocation and is cleaved between Thr20 and Gly21.[69] [70] The resulting mature protein, 441 amino acids of length, is subject to further post-translational modifications (PTMs). The sequence has 3 N-glycosylation sites (Asn38, Asn46, Asn53), which are all located in the non-cytoplasmic region flanked by the signal peptide and the first transmembrane domain.[71] Ridigity of the N-terminal region close to the membrane is increased by O-GalNAc at Thr25.[72] [73] O-GlcNAc at sites Ser227, Thr231, Ser445, and Ser459 are involved in the regulation of signaling pathways.[74] [75] In fact, Ser445 and Ser459 are also subject to phosphorylation, where both sites are associated with casein kinase II (CKII), suggesting a crosstalking network that regulates protein activity.[76] [77] [78] Other highly conserved phosphorylation sites include Thr166, Ser233, Ser253, and Ser454, which are most likely targeted by kinases protein kinase C (PKC), CKII, PKC, and CKI/II, respectively. Conserved glycation sites at epsilon amino groups of lysines are predicted at Lys101, Lys239, and Lys374 with possible disrupting effects on molecular conformation and function of the protein.[79] [80] S-palmitoylation, which help the protein bind more tightly to the membrane by contributing to protein hydrophobicity and membrane association, is predicted at Cys261 and Cys438.[81] [82] [83] [84] S-palmitoylation can also modulate protein-protein interactions of SLC46A3 by changing the affinity of the protein for lipid rafts.

Homology and Evolution

Paralogs

SLC46A1

Also known as the proton-coupled folate transporter, SLC46A3 transports folate and antifolate substrates across cell membranes in a pH-dependent manner.[85]

SLC46A2: Aliases include thymic stromal cotransporter homolog, TSCOT, and Ly110. SLC46A2 is involved in symporter activity[86] and is a transporter of the immune second messenger 2'3'-cGAMP.[87]

SLC46A3 Paralogs[88] !Paralog!Estimated Date of Divergence (MYA)!Accession Number!Sequence Length (aa)!Sequence Identity (%)!Sequence Similarity (%)
SLC46A1724NP_542400.24593149
SLC46A2810NP_149040.34752744

Orthologs

SLC46A3 is a highly conserved protein with orthologs as distant as fungi. Closely related orthologs have been found in mammals with sequence similarities above 75% while moderately related orthologs come from species of birds, reptiles, amphibians, and fish with sequence similarities of 50-70%. More distantly related orthologs have sequence similarities below 50% and are invertebrates, placozoa, and fungi. The MFS, MFS_1, and transmembrane domains mostly remain conserved throughout species. A selected list of orthologs obtained through NCBI BLAST is shown in the table below.

SLC46A3 Orthologs[89] !Genus and Species!Common Name!Taxonomic Group!Date of Divergence (MYA)!Accession Number!Sequence Length (aa)!Sequence Identity (%)!Sequence Similarity (%)
Homo sapiensHumanMammalia0NP_861450.1461100100
Macaca mulattaRhesus MonkeyMammalia29XP_014976295.24609596
Mus musculusHouse MouseMammalia90NP_001343931.14607586
Ornithorhynchus anatinusPlatypusMammalia177XP_028904425.14626881
Gallus gallusChickenAves312NP_001025999.14645169
Pseudonaja textilisEastern Brown SnakeReptilia312XP_026564717.14614463
Xenopus tropicalisTropical Clawed FrogAmphibia352XP_002934077.14734262
Danio rerioZebrafishActinopterygii435XP_021329877.14634262
Rhincodon typusWhale SharkChondrichthyes473XP_020383213.14563956
Anneissia japonicaFeather StarCrinoidea684XP_033118008.14662947
Pecten maximusGreat ScallopBivalvia797XP_033735180.15172440
Drosophila navojoaFruit FlyInsecta797XP_030245348.15951934
Nematostella vectensisStarlet Sea AnemoneAnthozoa824XP_001640625.15092846
Schmidtea mediterraneaFlatwormRhabditophora824AKN21695.14832338
Trichoplax adhaerensTrichoplaxTricoplacia948XP_002114167.14741936
Chytriomyces confervaeC. confervaeChytridiomycetes1105TPX75507.14982340
Tuber magnatumWhite TrufflePezizomycetes1105PWW79074.15572134
Cladophialophora bantianaC. bantianaEurotiomycetes1105XP_016623985.15872132
Exophiala mesophilaBlack YeastEurotiomycetes1105RVX69813.15931932
Aspergillus terreusMoldEurotiomycetes1105GES65939.16041931

Evolutionary History

The SLC46A3 gene first appeared in fungi approximately 1105 million years ago (MYA). It evolves at a relatively moderate speed. A 1% change in the protein sequence requires about 6.2 million years. The SLC46A3 gene evolves about 4 times faster than cytochrome c and 2.5 times slower than fibrinogen alpha chain.

Function

As an MFS protein, SLC46A3 is a membrane transporter, mainly involved in the movement of substrates across the lipid bilayer.[4] The protein works via secondary active transport, where the energy for transport is provided by an electrochemical gradient.[90]

A proposed function of SLC46A3 of rising importance is the direct transport of maytansine-based catabolites from the lysosome to the cytoplasm by binding the macrolide structure of maytansine.[91] Among the different types of antibody-drug conjugates (ADCs), maytansine-based noncleavable linker ADC catabolites, such as lysine-MCC-DM1, are particularly responsive to SLC46A3 activity. The protein functions independent of the cell surface target or cell line, thus is most likely to recognize maytansine or a moiety within the maytansine scaffold. Through transmembrane transport activity, the protein regulates catabolite concentration in the lysosome. In addition, SLC46A3 expression has been identified as a mechanism for resistance to ADCs with noncleavable maytansinoid and pyrrolobenzodiazepine warheads.[92] Although subcellular localization predictions have failed to identify the lysosome as a final destination of the protein, the YXXphi motif identified in the protein sequence has shown to direct lysosomal sorting.

SLC46A3 may be involved in plasma membrane electron transport (PMET), a plasma membrane analog of the mitochondrial electron transport chain (ETC) that oxidizes intracellular NADH and contributes to aerobic energy production by supporting glycolytic ATP production.[93] The 3' UTR region of SLC46A3 includes a binding site for ENOX1, a protein highly involved in PMET.[94] The C-(X)2-C motif in the protein sequence also suggests possible oxidoreductase activity.

Interacting Proteins

SLC46A3 has been found to generally interact with proteins involved in membrane transport, immune response, catalytic activity, or oxidation of substrates.[95] Some of the most definite and clinically important interactions include the following proteins.

Variants

SNPs are a very common type of genetic variation and are silent most of the time.[103] However, certain SNPs in the conserved or functionally important regions of the gene may have adverse effects on gene expression and function. Some of the SNPs with potentially damaging effects identified in the coding sequence of SLC46A3 are shown in the table below.

SNPs of SLC46A3[104] !SNP!mRNA position!Amino Acid Position!Base Change!Amino Acid Change!Function!Description
rs14560674445541[T/G][M/R]missensestart codon
rs74950187767946[A/G][N/S]missenseN-glycosylation site
rs776889950897119[T/G][C/G]missenseC-(X)2-C motif
rs1403613207967142[G/A][G/D]missenseconserved substrate translocation pore
rs7641984261322261[CT/-][C/F]frameshiftS-palmitoylation site
rs13737357931878446[T/C][Y/H]missenseYXXphi motif & STAP1 SH2 domain binding motif
rs13423276151906455[G/A][S/N]missensephosphorylation & O-GlcNAc site
rs757225275rs7519826481917459[T/G][T/-][S/A][S/Q]missenseframeshiftphosphorylation & O-GlcNAc site
f*The coordinates/positions are for GRCh38.p7.

Clinical Significance

Cancer/Tumor

The clinical significance of SLC46A3 surrounds the protein's activity as a transporter of maytansine-based ADC catabolites. shRNA screens employing two libraries identified SLC46A3 as the only hit as a mediator of noncleavable maytansine-based ADC-dependent cytotoxicity, with q-values of 1.18×10−9 and 9.01×10−3.[12] Studies show either lost or significantly reduced SLC46A3 expression (-2.79 fold decrease by microarray with p-value 5.80×10−8) in T-DM1 (DM1 payload attached to antibody trastuzumab)-resistant breast cancer cells (KPL-4 TR).[6] In addition, siRNA knockdown in human breast tumor cell line BT-474M1 also results in resistance to T-DM1. Such association between loss of SLC46A3 expression and resistance to ADCs also applies to pyrrolobenzodiazepine warheads, signifying the important role of SLC46A3 in cancer treatment.

CDP, one of SLC46A3's transcription factors, works as a tumor suppressor where CDP deficiency activates phosphoinositide 3-kinase (PI3K) signaling that leads to tumor growth.[105] The loss of heterozygosity and mutations of CDP are also associated with a variety of cancers.[106]

Prostate Cancer

Microarray analysis of SLC46A3 in two different prostate cancer cell lines, LNCaP (androgen-dependent) and DU145 (androgen-independent), show SLC46A3 expression in DU145 to be about 5 times as high as in LNCaP for percentile ranks and 1.5 times as high for transformed counts, demonstrating an association between SLC46A3 and accelerated cell growth of prostate cancer cells. SLC46A3 possibly contributes to the androgen-independent manner of cancer development.

Hepatocellular Carcinoma (HCC)

SLC46A3 was found to be down-regulated in 83.2% of human HCC tissues based on western blot scores and qRT-PCR results on mRNA expression (p < 0.0001). Overexpression of the gene also reduced resistance to sorafenib treatment and improved overall survival rate (p = 0.00085).

Papilloma & Glioma

Western blot analysis supports substantially strong expression of SLC46A3 in papilloma and glioma cells when compared to expression in the liver, one of the organs where the gene is most highly expressed.

Obesity

A genome-wide association study on obesity identified 10 variants in the flanking 5′UTR region of SLC46A3 that were highly associated with diet fat (% energy) (p = 1.36×10−6 - 9.57×10−6). In diet-induced obese (DIO) mice, SLC46A3 shows decreased gene expression following c-Jun N-terminal kinase 1 (JNK1) depletion, suggesting possible roles in insulin resistance as well as glucose/triglyceride homeostasis.[107]

SARS-CoV & SARS-CoV-2

Understanding the interaction between SLC46A3 and NSP2 in addition to the functions of each protein is critical to gaining insight into the pathogenesis of coronaviruses, namely SARS-CoV and SARS-CoV-2. The NSP2 protein domain resides in a region of the coronavirus replicase that is not particularly conserved across coronaviruses, and thus the altering protein sequence leads to significant changes in protein structure, leading to structural and functional variability.

See also

References

  1. Web site: SLC46A3. NCBI (National Center for Biotechnology Information) Gene.
  2. Web site: SLC46A3 Gene. GeneCards The Human Gene Database.
  3. Book: Nakai. Kenta . Horton. Paul . vanc . Computational Prediction of Subcellular Localization. Protein Targeting Protocols. Methods in Molecular Biology . 2007 . 390 . 429–466. Totowa, NJ. Humana Press. 10.1007/1-59745-466-4_29 . 978-1-58829-702-0.
  4. Web site: SLC46A3. OMIM (Online Mendelian Inheritance in Man).
  5. Web site: MFS. NCBI (National Center for Biotechnology Information) CDD (Conserved Domain Database).
  6. Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM, Lacap JA, Phillips GD . 6 . Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells . Molecular Cancer Therapeutics . 17 . 7 . 1441–1453 . July 2018 . 29695635 . 10.1158/1535-7163.mct-17-0296 . free .
  7. Kanaoka R, Kushiyama A, Seno Y, Nakatsu Y, Matsunaga Y, Fukushima T, Tsuchiya Y, Sakoda H, Fujishiro M, Yamamotoya T, Kamata H, Matsubara A, Asano T . 6 . Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines . PLOS ONE . 10 . 6 . e0127467 . 2015-06-03 . 26039047 . 10.1371/journal.pone.0127467 . 4454534 . 2015PLoSO..1027467K . free .
  8. Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y . 6 . Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy . Biomedicine & Pharmacotherapy . 114 . 108864 . June 2019 . 30981107 . 10.1016/j.biopha.2019.108864 . free .
  9. Web site: SLC46A3 Polyclonal Antibody. ThermoFisher Scientific.
  10. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, Butte NF . Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population . PLOS ONE . 7 . 12 . e51954 . 2012-12-14 . 23251661 . 10.1371/journal.pone.0051954 . 3522587 . 2012PLoSO...751954C . free .
  11. Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Wessels C, Pöhlmann S, Haas J, Drosten C, von Brunn A . 6 . The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors . PLOS Pathogens . 7 . 10 . e1002331 . October 2011 . 22046132 . 10.1371/journal.ppat.1002331 . 3203193 . free .
  12. Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, Milburn RR, Siu S, Ragan SP, Rock DA, Borths CJ, O'Neill JW, Chang WS, Weidner MF, Bio MM, Quon KC, Fanslow WC . 6 . SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm . Cancer Research . 75 . 24 . 5329–40 . December 2015 . 26631267 . 10.1158/0008-5472.can-15-1610 . free .
  13. Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjöstedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlén M . 6 . Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics . Molecular & Cellular Proteomics . 13 . 2 . 397–406 . February 2014 . 24309898 . 10.1074/mcp.m113.035600 . free . 3916642 .
  14. Duff MO, Olson S, Wei X, Garrett SC, Osman A, Bolisetty M, Plocik A, Celniker SE, Graveley BR . Genome-wide identification of zero nucleotide recursive splicing in Drosophila . Nature . 521 . 7552 . 376–9 . May 2015 . 25970244 . 4529404 . 10.1038/nature14475 . 2015Natur.521..376D .
  15. Web site: SLC46A3. AceView.
  16. Web site: BLAST: Basic Local Alignment Search Tool. NCBI (National Center for Biotechnology Information).
  17. Web site: Variation Viewer (GRCh38). NCBI (National Center for Biotechnology Information).
  18. Web site: SLC46A3. PAXdb.
  19. Web site: SLC46A3. Genomatix: ElDorado. 2020-08-01. 2021-08-26. https://web.archive.org/web/20210826023924/https://www.genomatix.de/cgi-bin/sessions/login.pl?s=1a35a28b07769763b98450d53a1f4aa8. dead.
  20. Book: Pruitt. Kim . Brown. Garth. Tatusova. Tatiana. Maglott. Donna . Donna R. Maglott. vanc . The Reference Sequence (RefSeq) Database. 2012-04-06. National Center for Biotechnology Information (US). en.
  21. Homo sapiens solute carrier family 46 member 3 (SLC46A3), transcript variant 1, mRNA. NCBI (National Center for Biotechnology Information) Nucleotide. 14 December 2020.
  22. Homo sapiens solute carrier family 46 member 3 (SLC46A3), transcript variant 2, mRNA. NCBI (National Center for Biotechnology Information) Nucleotide. 13 December 2020.
  23. Homo sapiens solute carrier family 46 member 3 (SLC46A3), transcript variant 3, mRNA. NCBI (National Center for Biotechnology Information) Nucleotide. 2 July 2020.
  24. PREDICTED: Homo sapiens solute carrier family 46 member 3 (SLC46A3), transcript variant X1, mRNA. NCBI (National Center for Biotechnology Information) Nucleotide. 16 May 2021.
  25. Web site: solute carrier family 46 member 3 isoform a precursor [Homo sapiens]]. NCBI (National Center for Biotechnology Information) Protein.
  26. Web site: solute carrier family 46 member 3 isoform a precursor [Homo sapiens]]. NCBI (National Center for Biotechnology Information) Protein.
  27. Web site: solute carrier family 46 member 3 isoform b precursor [Homo sapiens]]. NCBI (National Center for Biotechnology Information) Protein.
  28. Web site: solute carrier family 46 member 3 isoform X1 [Homo sapiens]]. NCBI (National Center for Biotechnology Information) Protein.
  29. Brendel V, Bucher P, Nourbakhsh IR, Blaisdell BE, Karlin S . Methods and algorithms for statistical analysis of protein sequences . Proceedings of the National Academy of Sciences of the United States of America . 89 . 6 . 2002–6 . March 1992 . 1549558 . 10.1073/pnas.89.6.2002 . 48584 . 1992PNAS...89.2002B . free .
  30. Book: Alberts. Bruce. Johnson. Alexander. Lewis. Julian. Raff. Martin. Roberts. Keith. Walter. Peter . vanc . 2002. Membrane Proteins. Molecular Biology of the Cell. . Garland Science . 4th . en.
  31. Miseta A, Csutora P . Relationship between the occurrence of cysteine in proteins and the complexity of organisms . Molecular Biology and Evolution . 17 . 8 . 1232–9 . August 2000 . 10908643 . 10.1093/oxfordjournals.molbev.a026406 . free .
  32. Kumar M, Gouw M, Michael S, Sámano-Sánchez H, Pancsa R, Glavina J, Diakogianni A, Valverde JA, Bukirova D, Čalyševa J, Palopoli N, Davey NE, Chemes LB, Gibson TJ . 6 . ELM-the eukaryotic linear motif resource in 2020 . Nucleic Acids Research . 48 . D1 . D296–D306 . January 2020 . 31680160 . 7145657 . 10.1093/nar/gkz1030 .
  33. Web site: TRG_ENDOCYTIC_2. ELM (The Eukaryotic Linear Motif resource for Functional Sites in Proteins).
  34. Pandey KN . Small peptide recognition sequence for intracellular sorting . Current Opinion in Biotechnology . 21 . 5 . 611–20 . October 2010 . 20817434 . 10.1016/j.copbio.2010.08.007 . 2997389 .
  35. Web site: LIG_SH2_STAP1. ELM (The Eukaryotic Linear Motif resource for Functional Sites in Proteins).
  36. Eisenberg D, Weiss RM, Terwilliger TC . The hydrophobic moment detects periodicity in protein hydrophobicity . Proceedings of the National Academy of Sciences of the United States of America . 81 . 1 . 140–4 . January 1984 . 6582470 . 10.1073/pnas.81.1.140 . 344626 . 1984PNAS...81..140E . free .
  37. Zimmermann L, Stephens A, Nam SZ, Rau D, Kübler J, Lozajic M, Gabler F, Söding J, Lupas AN, Alva V . 6 . A Completely Reimplemented MPI Bioinformatics Toolkit with a New HHpred Server at its Core . Journal of Molecular Biology . 430 . 15 . 2237–2243 . July 2018 . 29258817 . 10.1016/j.jmb.2017.12.007 . 22415932 .
  38. Book: Reithmeier, Reinhart A.F. . vanc . Assembly of proteins into membranes. 1996. Biochemistry of Lipids, Lipoproteins and Membranes. New Comprehensive Biochemistry . 31 . 425–471. Elsevier. 10.1016/s0167-7306(08)60523-2 . 978-0-444-82359-5.
  39. Biggin PC, Sansom MS . Interactions of alpha-helices with lipid bilayers: a review of simulation studies . Biophysical Chemistry . 76 . 3 . 161–83 . February 1999 . 10074693 . 10.1016/s0301-4622(98)00233-6 .
  40. Omasits U, Ahrens CH, Müller S, Wollscheid B . Protter: interactive protein feature visualization and integration with experimental proteomic data . Bioinformatics . 30 . 6 . 884–6 . March 2014 . 24162465 . 10.1093/bioinformatics/btt607 . free . 20.500.11850/82692 . free .
  41. Web site: Q7Z3Q1 (S46A3_HUMAN). UniProt.
  42. Yang J, Zhang Y . I-TASSER server: new development for protein structure and function predictions . Nucleic Acids Research . 43 . W1 . W174-81 . July 2015 . 25883148 . 10.1093/nar/gkv342 . 4489253 .
  43. Zhang Y, Skolnick J . TM-align: a protein structure alignment algorithm based on the TM-score . Nucleic Acids Research . 33 . 7 . 2302–9 . 2005-04-11 . 15849316 . 10.1093/nar/gki524 . 1084323 .
  44. Web site: I-TASSER results. Zhang Lab.
  45. Zhang C, Freddolino PL, Zhang Y . COFACTOR: improved protein function prediction by combining structure, sequence and protein-protein interaction information . Nucleic Acids Research . 45 . W1 . W291–W299 . July 2017 . 28472402 . 10.1093/nar/gkx366 . 5793808 .
  46. Yang J, Roy A, Zhang Y . Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment . Bioinformatics . 29 . 20 . 2588–95 . October 2013 . 23975762 . 10.1093/bioinformatics/btt447 . 3789548 .
  47. Book: Latchman, David S. . vanc . Methods for Studying Transcription Factors. 2004. Eukaryotic Transcription Factors. The Biochemical Journal . 270 . 2 . 23–53. Elsevier. 10.1016/b978-012437178-1/50008-4 . 2119171 . 1131717 . 978-0-12-437178-1.
  48. Web site: SLC46A3 Transcription Factor Binding Sites. Genomatix: MatInspector.
  49. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K . c-Myc and cancer metabolism . Clinical Cancer Research . 18 . 20 . 5546–53 . October 2012 . 23071356 . 3505847 . 10.1158/1078-0432.CCR-12-0977 .
  50. Ellis T, Gambardella L, Horcher M, Tschanz S, Capol J, Bertram P, Jochum W, Barrandon Y, Busslinger M . 6 . The transcriptional repressor CDP (Cutl1) is essential for epithelial cell differentiation of the lung and the hair follicle . Genes & Development . 15 . 17 . 2307–19 . September 2001 . 11544187 . 312776 . 10.1101/gad.200101 .
  51. Wang GZ, Zhang W, Fang ZT, Zhang W, Yang MJ, Yang GW, Li S, Zhu L, Wang LL, Zhang WS, Liu R, Qian S, Wang JH, Qu XD . 6332740 . 6 . Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro . Journal of Cancer Research and Clinical Oncology . 140 . 7 . 1125–36 . July 2014 . 24756364 . 10.1007/s00432-014-1659-6 .
  52. Web site: Illumina bodyMap2 transcriptome. NCBI (National Center for Biotechnology Information) BioProject.
  53. Szabo L, Morey R, Palpant NJ, Wang PL, Afari N, Jiang C, Parast MM, Murry CE, Laurent LC, Salzman J . 6 . Erratum to: Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development . Genome Biology . 17 . 1 . 263 . December 2016 . 27993159 . 10.1186/s13059-016-1123-9 . 5165717 . free .
  54. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB . 6 . A gene atlas of the mouse and human protein-encoding transcriptomes . Proceedings of the National Academy of Sciences of the United States of America . 101 . 16 . 6062–7 . April 2004 . 15075390 . 10.1073/pnas.0400782101 . 395923 . 2004PNAS..101.6062S . free .
  55. Web site: SLC46A3. GenePaint.
  56. Web site: SLC46A3 (Mouse Brain). Allen Brain Atlas.
  57. Web site: Slc46a3 ISH: Mus musculus, Male, P4, variable. Allen Brain Atlas.
  58. Web site: Slc46a3 ISH: Mus musculus, Male, P56, variable. Allen Brain Atlas.
  59. Brinegar AE, Cooper TA . Roles for RNA-binding proteins in development and disease . Brain Research . 1647 . 1–8 . September 2016 . 26972534 . 5003702 . 10.1016/j.brainres.2016.02.050 .
  60. Paz I, Kosti I, Ares M, Cline M, Mandel-Gutfreund Y . RBPmap: a web server for mapping binding sites of RNA-binding proteins . Nucleic Acids Research . 42 . Web Server issue . W361-7 . July 2014 . 24829458 . 10.1093/nar/gku406 . 4086114 .
  61. Macfarlane LA, Murphy PR . MicroRNA: Biogenesis, Function and Role in Cancer . Current Genomics . 11 . 7 . 537–61 . November 2010 . 21532838 . 10.2174/138920210793175895 . 3048316 .
  62. Chen Y, Wang X . miRDB: an online database for prediction of functional microRNA targets . Nucleic Acids Research . 48 . D1 . D127–D131 . January 2020 . 31504780 . 10.1093/nar/gkz757 . 6943051 .
  63. Web site: SLC46A3. miRDB.
  64. Vandivier LE, Anderson SJ, Foley SW, Gregory BD . The Conservation and Function of RNA Secondary Structure in Plants . Annual Review of Plant Biology . 67 . 1 . 463–88 . April 2016 . 26865341 . 10.1146/annurev-arplant-043015-111754 . 5125251 .
  65. Book: 1993. Control of Messenger RNA Stability. 10.1016/c2009-0-03269-3. 9780120847822.
  66. Zuker M . Mfold web server for nucleic acid folding and hybridization prediction . Nucleic Acids Research . 31 . 13 . 3406–15 . July 2003 . 12824337 . 10.1093/nar/gkg595 . 169194 .
  67. Book: Nakai. Kenta . Horton. Paul. vanc . Computational Prediction of Subcellular Localization. Protein Targeting Protocols. Methods in Molecular Biology . 2007 . 390 . 429–466. Totowa, NJ. Humana Press. 10.1007/1-59745-466-4_29 . 978-1-58829-702-0.
  68. 2014. The Cell: A Molecular Approach. Sixth Edition. By Geoffrey M. Cooper and Robert E. Hausman. Sunderland (Massachusetts): Sinauer Associates. $142.95. xxv + 832 p.; ill.; index. [A Companion Website is available.] 2013.. 978-0-87893-964-0. The Quarterly Review of Biology. 89. 4. 399. 10.1086/678645. 0033-5770.
  69. Almagro Armenteros JJ, Tsirigos KD, Sønderby CK, Petersen TN, Winther O, Brunak S, von Heijne G, Nielsen H . 216678118 . 6 . SignalP 5.0 improves signal peptide predictions using deep neural networks . Nature Biotechnology . 37 . 4 . 420–423 . April 2019 . 30778233 . 10.1038/s41587-019-0036-z .
  70. Käll L, Krogh A, Sonnhammer EL . A combined transmembrane topology and signal peptide prediction method . Journal of Molecular Biology . 338 . 5 . 1027–36 . May 2004 . 15111065 . 10.1016/j.jmb.2004.03.016 .
  71. Book: Julenius. Karin . Johansen. Morten B.. Zhang. Yu. Brunak. Sren. Gupta. Ramneek . vanc . Prediction of Glycosylation Sites in Proteins. Bioinformatics for Glycobiology and Glycomics. 2009 . 163–192. Chichester, UK. John Wiley & Sons, Ltd. 10.1002/9780470029619.ch9 . 978-0-470-02961-9.
  72. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, Gupta R, Bennett EP, Mandel U, Brunak S, Wandall HH, Levery SB, Clausen H . 6 . Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology . The EMBO Journal . 32 . 10 . 1478–88 . May 2013 . 23584533 . 10.1038/emboj.2013.79 . 3655468 .
  73. Book: Essentials of glycobiology. Varki, Ajit. 2017. 978-1-62182-132-8. Third. Cold Spring Harbor, New York. 960166742.
  74. Gupta R, Brunak S . Prediction of glycosylation across the human proteome and the correlation to protein function . Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing . 310–22 . 2001 . 11928486 . 10.1142/9789812799623_0029 . WORLD SCIENTIFIC . 978-981-02-4777-5 .
  75. Fisi V, Miseta A, Nagy T . The Role of Stress-Induced O-GlcNAc Protein Modification in the Regulation of Membrane Transport . Oxidative Medicine and Cellular Longevity . 2017 . 1308692 . 2017 . 29456783 . 10.1155/2017/1308692 . 5804373 . free .
  76. Wang C, Xu H, Lin S, Deng W, Zhou J, Zhang Y, Shi Y, Peng D, Xue Y . 6 . GPS 5.0: An Update on the Prediction of Kinase-specific Phosphorylation Sites in Proteins . Genomics, Proteomics & Bioinformatics . 18 . 1 . 72–80 . February 2020 . 32200042 . 10.1016/j.gpb.2020.01.001 . 7393560 . free .
  77. Blom N, Gammeltoft S, Brunak S . Sequence and structure-based prediction of eukaryotic protein phosphorylation sites . Journal of Molecular Biology . 294 . 5 . 1351–62 . December 1999 . 10600390 . 10.1006/jmbi.1999.3310 .
  78. Blom N, Sicheritz-Pontén T, Gupta R, Gammeltoft S, Brunak S . Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence . Proteomics . 4 . 6 . 1633–49 . June 2004 . 15174133 . 10.1002/pmic.200300771 . 18810164 .
  79. Johansen MB, Kiemer L, Brunak S . Analysis and prediction of mammalian protein glycation . Glycobiology . 16 . 9 . 844–53 . September 2006 . 16762979 . 10.1093/glycob/cwl009 . free .
  80. Chen JH, Lin X, Bu C, Zhang X . Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies . Nutrition & Metabolism . 15 . 1 . 72 . 2018-10-10 . 30337945 . 10.1186/s12986-018-0306-7 . 6180645 . free .
  81. Xie Y, Zheng Y, Li H, Luo X, He Z, Cao S, Shi Y, Zhao Q, Xue Y, Zuo Z, Ren J . 6 . GPS-Lipid: a robust tool for the prediction of multiple lipid modification sites . Scientific Reports . 6 . 1 . 28249 . June 2016 . 27306108 . 10.1038/srep28249 . 4910163 . 2016NatSR...628249X .
  82. Aicart-Ramos C, Valero RA, Rodriguez-Crespo I . Protein palmitoylation and subcellular trafficking . Biochimica et Biophysica Acta (BBA) - Biomembranes . 1808 . 12 . 2981–94 . December 2011 . 21819967 . 10.1016/j.bbamem.2011.07.009 . free .
  83. Ren J, Wen L, Gao X, Jin C, Xue Y, Yao X . CSS-Palm 2.0: an updated software for palmitoylation sites prediction . Protein Engineering, Design & Selection . 21 . 11 . 639–44 . November 2008 . 18753194 . 10.1093/protein/gzn039 . 2569006 .
  84. Guan X, Fierke CA . Understanding Protein Palmitoylation: Biological Significance and Enzymology . Science China Chemistry . 54 . 12 . 1888–1897 . December 2011 . 25419213 . 10.1007/s11426-011-4428-2 . 4240533 .
  85. Web site: SLC46A1. NCBI (National Center for Biotechnology Information) Gene.
  86. Web site: SLC46A2. NCIB (National Center for Biotechnology Information) Gene.
  87. Cordova . Anthony F. . Ritchie . Christopher . Böhnert . Volker . Li . Lingyin . Human SLC46A2 Is the Dominant cGAMP Importer in Extracellular cGAMP-Sensing Macrophages and Monocytes . ACS Cent Sci . June 23, 2021 . 7 . 6 . 1073–1088 . 10.1021/acscentsci.1c00440 . 34235268. 8228594 .
  88. Needleman SB, Wunsch CD . A general method applicable to the search for similarities in the amino acid sequence of two proteins . Journal of Molecular Biology . 48 . 3 . 443–53 . March 1970 . 5420325 . 10.1016/0022-2836(70)90057-4 .
  89. Kumar S, Stecher G, Suleski M, Hedges SB . TimeTree: A Resource for Timelines, Timetrees, and Divergence Times . Molecular Biology and Evolution . 34 . 7 . 1812–1819 . July 2017 . 28387841 . 10.1093/molbev/msx116 . free .
  90. Pao SS, Paulsen IT, Saier MH . Major facilitator superfamily . Microbiology and Molecular Biology Reviews . 62 . 1 . 1–34 . March 1998 . 9529885 . 10.1128/mmbr.62.1.1-34.1998 . 98904 .
  91. Bissa B, Beedle AM, Govindarajan R . Lysosomal solute carrier transporters gain momentum in research . Clinical Pharmacology and Therapeutics . 100 . 5 . 431–436 . November 2016 . 27530302 . 10.1002/cpt.450 . 5056150 .
  92. Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA . 6 . SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads . Clinical Cancer Research . 24 . 24 . 6570–6582 . December 2018 . 30131388 . 10.1158/1078-0432.ccr-18-1300 . free .
  93. Herst PM, Berridge MV . Plasma membrane electron transport: a new target for cancer drug development . Current Molecular Medicine . 6 . 8 . 895–904 . December 2006 . 17168740 . 10.2174/156652406779010777 . 2020-08-01 .
  94. Web site: ENOX1 ecto-NOX disulfide-thiol exchanger 1 [Homo sapiens (human) ]]. NCBI (National Center for Biotechnology Information) Gene.
  95. Figure S6: Predicted secondary structure of CoV-RMEN using CFSSP:Chou and Fasman secondary structure prediction server. 10.7717/peerj.9572/supp-13. free.
  96. Luck K, Kim DK, Lambourne L, Spirohn K, Begg BE, Bian W, Brignall R, Cafarelli T, Campos-Laborie FJ, Charloteaux B, Choi D, Coté AG, Daley M, Deimling S, Desbuleux A, Dricot A, Gebbia M, Hardy MF, Kishore N, Knapp JJ, Kovács IA, Lemmens I, Mee MW, Mellor JC, Pollis C, Pons C, Richardson AD, Schlabach S, Teeking B, Yadav A, Babor M, Balcha D, Basha O, Bowman-Colin C, Chin SF, Choi SG, Colabella C, Coppin G, D'Amata C, De Ridder D, De Rouck S, Duran-Frigola M, Ennajdaoui H, Goebels F, Goehring L, Gopal A, Haddad G, Hatchi E, Helmy M, Jacob Y, Kassa Y, Landini S, Li R, van Lieshout N, MacWilliams A, Markey D, Paulson JN, Rangarajan S, Rasla J, Rayhan A, Rolland T, San-Miguel A, Shen Y, Sheykhkarimli D, Sheynkman GM, Simonovsky E, Taşan M, Tejeda A, Tropepe V, Twizere JC, Wang Y, Weatheritt RJ, Weile J, Xia Y, Yang X, Yeger-Lotem E, Zhong Q, Aloy P, Bader GD, De Las Rivas J, Gaudet S, Hao T, Rak J, Tavernier J, Hill DE, Vidal M, Roth FP, Calderwood MA . 6 . A reference map of the human binary protein interactome . Nature . 580 . 7803 . 402–408 . April 2020 . 32296183 . 7169983 . 10.1038/s41586-020-2188-x . 2020Natur.580..402L .
  97. Web site: CD79A CD79a molecule [Homo sapiens (human) ]]. NCBI (National Center for Biotechnology Information) Gene.
  98. Web site: P11912 (CD79A_HUMAN). UniProt.
  99. Huttlin EL, Ting L, Bruckner RJ, Gebreab F, Gygi MP, Szpyt J, Tam S, Zarraga G, Colby G, Baltier K, Dong R, Guarani V, Vaites LP, Ordureau A, Rad R, Erickson BK, Wühr M, Chick J, Zhai B, Kolippakkam D, Mintseris J, Obar RA, Harris T, Artavanis-Tsakonas S, Sowa ME, De Camilli P, Paulo JA, Harper JW, Gygi SP . 6 . The BioPlex Network: A Systematic Exploration of the Human Interactome . Cell . 162 . 2 . 425–440 . July 2015 . 26186194 . 10.1016/j.cell.2015.06.043 . 4617211 .
  100. Web site: LGALS3 galectin 3 [Homo sapiens (human) ]]. NCBI (National Center for Biotechnology Information) Gene.
  101. Book: Graham RL, Sims AC, Baric RS, Denison MR . The Nidoviruses . The NSP2 Proteins of Mouse Hepatitis Virus and Sars Coronavirus are Dispensable for Viral Replication . Advances in Experimental Medicine and Biology . 581 . 67–72 . 2006 . 17037506 . 10.1007/978-0-387-33012-9_10 . Springer US . 7123188 . 978-0-387-26202-4 . Boston, MA .
  102. 2020-04-07. Review for "Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2 or COVID -19)". 10.1111/dom.14062/v1/review3. 219115750 .
  103. Shen LX, Basilion JP, Stanton VP . Single-nucleotide polymorphisms can cause different structural folds of mRNA . Proceedings of the National Academy of Sciences of the United States of America . 96 . 14 . 7871–6 . July 1999 . 10393914 . 10.1073/pnas.96.14.7871 . 22154 . 1999PNAS...96.7871S . free .
  104. Web site: SNP linked to Gene (geneID:283537) Via Contig Annotation. NCBI (National Center for Biotechnology Information) dbSNP Short Genetic Variations.
  105. Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C, Green AR, Massie CE, Nangalia J, Lempidaki S, Döhner H, Döhner K, Bray SJ, McDermott U, Papaemmanuil E, Campbell PJ, Adams DJ . 6 . Inactivating CUX1 mutations promote tumorigenesis . Nature Genetics . 46 . 1 . 33–8 . January 2014 . 24316979 . 10.1038/ng.2846 . 3874239 .
  106. Liu N, Sun Q, Wan L, Wang X, Feng Y, Luo J, Wu H . CUX1, A Controversial Player in Tumor Development . Frontiers in Oncology . 10 . 738 . 2020-05-29 . 32547943 . 10.3389/fonc.2020.00738 . 7272708 . free .
  107. Yang R, Wilcox DM, Haasch DL, Jung PM, Nguyen PT, Voorbach MJ, Doktor S, Brodjian S, Bush EN, Lin E, Jacobson PB, Collins CA, Landschulz KT, Trevillyan JM, Rondinone CM, Surowy TK . 6 . Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice . The Journal of Biological Chemistry . 282 . 31 . 22765–74 . August 2007 . 17550900 . 10.1074/jbc.m700790200 . free .

Further reading